Celldex Therapeutics CLDX Institutional Ownership

Updated Oct 11, 2026

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was held by 253 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Total shares held in Celldex Therapeutics rose 17.31% from Q1 2026, while the number of holders rose 45.40% from Q2 2025.
• Among the 253 holders of Celldex Therapeutics, 156 added to their positions, 57 reduced their stakes and 40 left their positions unchanged.
• The aggregate institutional position in Celldex Therapeutics was 85.03Mn shares at the end of Q2 2026, up 12.54Mn from the prior quarter and up 14.1Mn from a year earlier.
• Wellington Management Group LLP was the top holder of Celldex Therapeutics as of June 30, 2026, with 9.54Mn shares.
• Among existing holders, the largest additions to Celldex Therapeutics in Q2 2026 came from T. Rowe Price Associates Inc (+2.6Mn shares), Deep Track Capital, LP (+1.66Mn shares), Logos Global Management LP (+1.65Mn shares), BlackRock, Inc. (+1.63Mn shares) and State Street Corp (+1.1Mn shares).
• The biggest cuts to CLDX positions during Q2 2026 came from Point72 Asset Management, L.P. (-3.11Mn shares), Commodore Capital LP (-1.35Mn shares), Braidwell LP (-919.44K shares), Kynam Capital Management, LP (-517.66K shares) and Novo Holdings A/S (-175K shares).
• Per Business Quant, the top 10 investors in CLDX for the quarter ended June 30, 2026 were Wellington Management Group LLP (9.54Mn shares), BlackRock, Inc. (7Mn shares), Kynam Capital Management, LP (5.32Mn shares), T. Rowe Price Associates Inc (4.69Mn shares), State Street Corp (3.9Mn shares), FMR LLC (3.72Mn shares), Vanguard Capital Management LLC (3.46Mn shares), Deep Track Capital, LP (2.94Mn shares), Logos Global Management LP (2.1Mn shares) and Geode Capital Management, LLC (2.02Mn shares).